Connect with us

Uncategorized

Meta Materials Inc (OTCMKTS: MMTLP) Short Squeeze S-1a4 Filing Signals S1 Approval Could Be Days Away (Next Bridge Hydrocarbons Spin-Off)

Published

on

Meta Materials Inc (OTCMKTS: MMTLP) had an enormous day on Wednesday rocketing to highs of $9.95 in the afternoon before another short attack near the close brought it under $9 again for a close of $8.85 per share. The Company filed an S-1a4 on November 9 and the only changes from the S-1a3 is the filing included 9 months of data versus 6 months of data signaling we could be days away from S1 approval. 

Our thoughts on MMTLP and what happened: 

As everyone knows by now MMTLP was halted and will not resume trading again. If you go on YouTube there are dozens of videos now saying that FINRA is corrupt and working with the hedge funds to screw the little guy and that what happened to MMTLP is “unprecedented” and nothing like this happens on the bulletin boards.    

This of course is not what happened FINRA is not corrupt and they are not working with anyone. FINRA rightfully halted the stock to protect shareholders who would have bought MMTLP after the 8th because anyone buying after the 8th did not get the Nextbridge shares and would have been buying an empty placeholder. Everyone who was invested in MMTLP will now be shareholders in Nextbridge Hydrocarbons, a private Company.

As for the short squeeze, we believed just like everyone else, MMTLP was skyrocketing up the charts, dozens of YouTube channels, stock twits, reddit everywhere else all saying the same. Youtube Bird lady rollerpigions saying there was millions of MMTLP shares short and then the Torchlight CEO John Brda appearing on multiple live streams with Bird Lady agreeing with everything she was saying and going as far as saying that “everything Bird Lady was saying was right over the bullseye” this gave her an air of legitimacy, we believed her.

We have now listened to the logic of the youtubers and one thing they all seem to miss is that MMTLP was not trading like a stock that had this enormous short position stuck in it during the last week. If an enormous short position of 10s of millions of shares had to cover in days, they would have been covering a long time ago. The last day that MMTLP traded last Thursday it lost almost half its value, relentless selling. Investors saw the writing on the wall, there was no short squeeze happening here and they were selling.  We have come to the conclusion that there never was a short position on MMTLP and in the coming days when they balance the books, we believe that’s exactly what they will show. FINRA was is just doing its job. 

Once the S1 is approved shorts will have 15 days to cover the 80 million shares sold short and if they don’t cover their broker will cover the shares for them. When that happens and the brokers are just dumping shares as Houston Wade points out, “we will see, perhaps, just astronomical prices” For 80 million shares to cover we will see a massive increase in trading volume and ultimately the brokers will pay whatever price they have to. 

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Meta Materials Inc (OTCMKTS: MMTLP) is the placeholder for the Next Bridge Hydrocarbons Spin off from Meta Materials. One MMTLP (Series A Preferred share) will be exchanged into one Next Bridge common share once the spinoff is completed.

Next Bridge Hydrocarbons is exclusively developing its Orogrande Basin asset, the Orogrande Project, located in West Texas. The Orogrande Project has shown to have potential for multi-stack pay zone, totaling 600 to 800 feet thick, with geologic and reservoir similarities to the Midland Basin. 134,000 Net Acres, 3,150 Potential.

MMTLP continues to be among the main topics discussed on the sub reddit ShortSqueeze; recently NinjaPwease u/dbCaeBLe posted: “MMTLP – Haven’t sold a single share. We haven’t even started to squeeze yet. This is just smart FOMO. Liftoff imminent. 

_SCHULTZY_ replied: “The assets could be worth significantly more than the current price. The reason for this is the preferred share was never meant to be tradable on the market it was a result of holding through the merger. The oil and gas assets are technically still “unproven” but it’s believed they have 3.2 BILLION barrels of oil and this will quickly change once it’s off Meta Materials books and into its own private company NextBridge Hydrocarbons. Basically they’re undervaluing it now to prevent the tax implications of the assets once they become proven. We’re currently waiting for the SEC to approve that S1 paperwork which starts the squeeze.
So basically it’s a short squeeze with a safety net. If the squeeze doesn’t work out and you hold, then you end up with shares in a private oil and gas company that’s looking for a big energy company to buy them out.
Why are they shorting? They need the shares to buy back but many are held by insiders, in foreign markets that can’t buy or sell OTC or already direct registered for the private company. Shorts have been attacking it to discourage people into selling their shares because they need millions of them to close their positions before this goes private.

https://twitter.com/AShortSqueeze/status/1592179014583857152

To Find out the inside Scoop on MMTLP Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

MMTLP

https://twitter.com/brad_shar/status/1591168904147374080

Rollerpigeons stated:I believe the assets to have significant value, I have calculated that value to be $32 to $60 per Nextbridge share, that’s what I believe it to be. I have fact tested this across numerous people and different entities and they all seem to nod their head in agreement but you know they can spin anything into negative news. I think now it’s just a matter of holding tight, we will very shortly see a finality to MMTLP trading. Next steps are we are going to see something with dates on it, and then we are going to see a pr come out from either Nextbridge or Meta talking about the new record date for shareholders. The way this works is, MMTLP shares will be cancelled out and you will be given equity in Nextbridge Hydrocarbons.”  

MarketMoves states:The only thing that I see that has changed is we now have 9 months of data versus 6 months and I’m guessing its because the SEC took to so long to approve this. So thank you John Brda for your tweet, you basically summarized everything that need to be said. I think we are getting very close to approval on the S1 from the SEC because there are very few changes here, there is just 9 months of date versus 6 months of data. We are looking at 1 week or less. Why do I say this? Well, we can look at what Wilmerhale has to say, they are a prominent law firm in Silicon Valley and they say the lapse time and the Sl4 filing and the SEC comments should be very, very quick. We are in the fourth comment letter right. We could be done in 3 days.”  

https://twitter.com/AShortSqueeze/status/1591140605626929154

  For More on MMTLP Subscribe Right Now!

Currently making a powerful run up the charts MMTLP had an enormous day on Wednesday rocketing to highs of $9.95 in the afternoon before another short attack near the close brought it under $9 again for a close of $8.85 per share.  As we wait on the S-1 to be approved MMTLP is now the number #1 trending stock on Stocktwits and the Shortsqueeze subreddit. As we said we could be days away from approval now that the Company has filed the S-1a4 and the only changes from the S-1a3 is the filing included 9 months of data versus 6 months of data. Then the 15-day countdown to privatization begins and 80 million shares currently sold short will have to be covered; this is when the real short squeeze will happen. We will be updating on MMTLP when anything new happens so make sure you are subscribed to microcapdaily.com

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in MMTLP either long or short and we have not been compensated for this article.

Continue Reading
4 Comments

4 Comments

  1. Jack Meoff

    November 16, 2022 at 7:02 am

    LOL. This is complete nonsense.
    The longs are going to get rug pulled as usual while the penny fraud pump and dumpers are laughing all the way to the bank.

    When will you people learn???

  2. Boe Rimes

    November 16, 2022 at 7:16 am

    Its red hot right now!

  3. B

    November 19, 2022 at 1:34 am

    The part everyone misses is most people think the shorts need to cover but they forget to realize that their brokerage firms won’t let them hold shares of a private company once this transaction happens so the longs will be forced to liquidate also thereby covering any shorts. I can tell management is planning to jump on all this nonsense and issue more shares at the higher price just like last time at the expense of their shareholders.

  4. Boe Rimes

    November 19, 2022 at 3:22 am

    This is incorrect. While you are 100% correct that the short have to cover in the next 15 business days now that the S1 is approved or will be Monday the longs don’t have to sell, if they don’t sell their shares, they will have shares in the private Company.

Leave a Reply

Your email address will not be published. Required fields are marked *

Featured

First Wave BioPharma’s (NASDAQ: FWBI) Exclusive License: Repurposing Capeserod for GIT Disorder Solutions

Published

on

First Wave BioPharma (NASDAQ: FWBI) experienced an impressive pre-market surge of approximately 85% on Thursday following the announcement of a licensing agreement with Sanofi (NASDAQ: SNY) concerning Capeserod, a potential treatment for gastrointestinal tract (GIT) disorders.

The Agreement:

According to the terms of the agreement, the biotech company based in Boca Raton, Florida, will obtain an exclusive global license for Capeserod from the French pharmaceutical giant and assume responsibility for its clinical development in exchange for an initial payment described as “modest.” Additionally, there will be further payments tied to developmental milestones and single-digit royalties based on net sales. Sanofi (SNY) will retain the right of first refusal for the future commercialization of Capeserod.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below. 

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Sanofi’s research on Capeserod, backed by cutting-edge artificial intelligence (AI) analysis, suggests that this drug could be a game-changer for a range of gastrointestinal disorders. These conditions represent massive markets with significant unmet medical needs. It’s like discovering a potential solution to some major health challenges.

Capeserod:

Sanofi has a track record with Capeserod, having already conducted seven Phase 1 and two Phase 2 trials to explore its potential in treating neurological disorders. These trials involved over 600 patients, and the good news is that Capeserod showed itself to be safe and well-tolerated. That’s a promising start.

Now, First Wave is eager to get things moving. They’re planning to reach out to the U.S. Food and Drug Administration (FDA) for a meeting as soon as possible. The goal? To hash out a clear plan for developing and regulating Capeserod for gastrointestinal diseases. They’re hoping to kick off clinical trials in 2024, which could be a big step forward in bringing this potential treatment to those who need it.

About First Wave Biopharma:

 

First Wave BioPharma is a company focused on developing specialized treatments for gastrointestinal (GI) diseases. They’re currently in the clinical-stage, meaning they’re actively testing their therapies on patients to make sure they work effectively.

They have two unique technologies they’re working with. The first one is called adrulipase, which is a special enzyme designed to help people digest fats and other nutrients better. The goal is to make it easier for people with GI issues to absorb these essential elements.

The second technology is niclosamide, a small molecule taken orally. It’s got anti-inflammatory properties, which means it can help reduce inflammation in the body.

Right now, First Wave is especially interested in adrulipase. They’re running Phase 2 clinical trials for it, focusing on patients dealing with exocrine pancreatic insufficiency (FW-EPI). This condition often affects people with cystic fibrosis (CF) and chronic pancreatitis (CP). The hope is that adrulipase can provide these patients with a safe and effective treatment option that doesn’t rely on animal-derived substances, and it might even reduce the number of pills they need to take every day.

But that’s not all. First Wave is also working on multiple programs involving niclosamide. They’re exploring its potential for ulcerative proctitis, ulcerative proctosigmoiditis, ulcerative colitis, and Crohn’s disease, all of which fall under the GI disease umbrella.

In a nutshell, First Wave BioPharma is on a mission to create better, more targeted treatments for GI diseases, and they’ve got some promising candidates in their pipeline.

Their latest collaboration with Sanofi hopes to repurpose Capeserod and focus on its development for various gastrointestinal indications. The company has initiated discussions with the FDA to map out a development and regulatory roadmap for Capeserod, with Phase 2 clinical trials slated to commence in 2024.

We will update you on FWBI when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by jarmoluk from Pixabay

Continue Reading

Featured

Mullen Automotive, Inc (NASDAQ: MULN): Investor Interest Continues to Surge, But Challenges Persist

Published

on

Mullen Automotive, Inc. (NASDAQ: MULN) has been experiencing significant investor interest in recent months, but its share price has yet to reflect positive fluctuations. The company is actively making headlines and expanding rapidly across various EV verticals globally. Despite announcing a $25 million stock buyback program, MULN’s valuation has not appreciated considerably, remaining at around $100 million market capitalization at time of writing. 

While Mullen’s management team asserts that they are undervalued, their stock price hovers at a meager ~$0.15 per share, falling below Nasdaq’s minimum bid compliance. With a cash position of approximately $235 million, the company shows promise, but further research is needed to understand potential obstacles hindering their growth. Let’s delve into a condensed overview of their news flow to grasp the extent of their growth throughout July and the tail end of June.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

July 18th, 2023

A company MULN acquired a majority interest in, called “Bollinger Motors” launched its “design validation” pilot builds for the B4 all-electric Class 4 chassis cabs, aimed at testing and demonstration purposes. The pilot vehicles are being manufactured in collaboration with Roush Industries, Inc. in Livonia, Michigan. The company expects to roll out the first five completed chassis cabs this summer, followed by over 15 vehicles by the end of Q3 2023. The B4, designed with extensive experience in all-electric truck development, offers limitless upfit options for fleet customers and will be showcased at a demonstration event in September. Additionally, the B4 will qualify for a federal purchasing incentive, providing up to 30% of the vehicle’s cost, capped at $40,000, with deliveries set to begin in July 2024.

https://twitter.com/NashMadeit_126/status/1681415557222940696?s=20

July 17th, 2023

Mullen Automotive, Inc. (NASDAQ: MULN) has received a 30-unit order for its Mullen-GO™ Commercial Urban Delivery EV from Newgate Motor Group, marking the first sale of Mullen vehicles in Europe. Newgate, a respected dealership group based in Ireland, will handle marketing, sales, distribution, and servicing for the Mullen-GO in Ireland and the United Kingdom. The Mullen-GO, designed for quick deliveries in European cities, is fully certified and ready for sale in initial markets such as the U.K., Germany, Spain, France, and Ireland. Newgate Motor Group, with over 40 years of experience, represents reputable brands and offers top-notch service at its facility in Navan.

July 16th, 2023

Mullen Automotive (NASDAQ: MULN), initiates the transfer of its Class 1 EV cargo van vehicles from its Indiana plant to its Mississippi plant for final assembly. With over 350 vehicles already transferred and another 300 scheduled for transfer this year, the Tunica plant is nearing the production start and deliveries of Class 1 and Class 3 vehicles. Mullen Automotive’s CEO and chairman, David Michery, expressed excitement about delivering vehicles to customers starting in August 2023, anticipating continued revenue growth throughout the last six months of the year. The Southern California-based automotive company is focused on developing the next generation of electric vehicles, including the Mullen FIVE EV Crossover, Mullen-GO Commercial Urban Delivery EV, Mullen commercial Class 13 EVs, and Bollinger Motors, featuring electric SUV trucks and Class 46 commercial offerings.

https://twitter.com/CrozzTrade/status/1680956372001718274?s=20

July 13th, 2023

Mullen Automotive, Inc. (NASDAQ: MULN) launches an EV pilot program in collaboration with New York Power Authority (NYPA). Commencing on July 6, 2023, NYPA is conducting tests on Mullen’s all-electric Campus Delivery Utility Vehicle, the EV Cargo Van, at its upstate New York location. As a leading power generation and transmission company committed to clean energy in New York, NYPA’s 2030 Vision aims for a thriving, resilient state powered by clean energy. Mullen’s Chief Commercial Officer, John Schwegman, expressed excitement about partnering with NYPA to work towards eliminating carbon emissions in New York, emphasizing the significance of sustainable initiatives in various states. Mullen’s CEO and Chairman, David Michery, echoed the excitement about entering the utility provider market with their EVs, specifically noting the suitability of the EV cargo van for closed workplace campus scenarios. The Mullen CAMPUS, designed for low-speed, closed campus use, is a highly efficient electric van aligned with NYPA’s efforts towards sustainability. As the largest state public power organization in the nation, NYPA operates multiple generating facilities and transmission lines, with over 80% of its electricity produced from clean renewable hydropower. NYPA funds its operations through bond sales and electricity revenues.

July 11th, 2023

Mullen Automotive, Inc. (NASDAQ: MULN) introduces PowerUP, its new mobile EV charging truck capable of providing both level 2 and level 3 DC fast charging to electric vehicles in scenarios where power is limited or unavailable, such as roadside assistance and emergency response situations. The PowerUP will be featured on Mullen’s upcoming 2023 “Strikingly Different” EV Tour, providing fast charging capabilities to Mullen’s EVs during the tour. The mobile charging truck, based on a Class 5 truck platform, offers up to 150kW of continuous power generation, equipped with two level 3 DC fast chargers and four level 2 chargers. Mullen plans to offer different configurations of the PowerUP for immediate sale via advance order, making it available for commercial applications and emergency teams. The EV tour, starting in August 2023, will cover various locations on the East Coast, Midwest, Northwest, and West Coast, showcasing Mullen’s lineup of electric vehicles, including the ultra-high-performance Mullen FIVE RS with a top speed of over 200 mph and acceleration from 0-60 mph in just 1.95 seconds.

https://twitter.com/Sam1am1911/status/1679476765155282950?s=20

July 5th, 2023

Mullen Automotive, Inc. (NASDAQ: MULN) enlists the services of Christian Attar, also known as Christian Levine Law Group, in partnership with Warshaw, Burstein, LLP, to address and combat potential illegal naked short selling activities targeting the company’s common stock. In response to reports received from ShareIntel indicating possible market manipulation schemes, Mullen intends to investigate and expose any wrongdoing involved. Christian Attar and Warshaw Burstein have a track record of successfully prosecuting and securing substantial damages against broker-dealers, market-makers, hedge funds, and asset-based lenders engaged in such market manipulation practices. Mullen’s CEO and Chairman, David Michery, emphasizes their active efforts in investigating naked short selling and their determination to take appropriate legal action against market manipulators employing illegal tactics like naked short selling and spoofing. Christian Attar operates internationally and domestically, with its headquarters located in Houston, Texas, specializing in various civil litigation cases, including shareholder disputes, partnership disputes, and stock fraud.

June 29th, 2023

Mullen Automotive, Inc. (NASDAQ: MULN) achieves a notable milestone with the sale of 22 EV cargo vans to the Randy Marion Automotive Group, resulting in a recorded revenue of $308,000 for the quarter ending June 30, 2023. All vehicles are scheduled for shipment, with the first batch departing on June 29, 2023, from Mullen’s assembly plant in Tunica, Mississippi, to the Randy Marion Automotive Group in North Carolina, the authorized distributor of Mullen’s commercial EVs in the U.S. The company is also actively pursuing six Campus EV Pilot Programs in various industries, with further details expected in future announcements. The Mullen commercial team has been engaging in national events, showcasing Class 1 and Class 3 vehicles, and plans to present its commercial vehicle lineup during the 2023 “Strikingly Different” U.S. tour starting in August 2023. Mullen’s CEO and Chairman, David Michery, regards these shipments as a significant achievement, marking the company’s first recorded revenue on the financial statement, which will be reflected in the June 30, 2023, 10-Q report.

Insights from InvestorPlace: A Concise Overview

InvestorPlace wrote a bearish article on MULN, here’s the consolidated version: Mullen Automotive’s (NASDAQ: MULN) stock has faced a significant decline after its removal from the Russell 2000 Index due to failure to meet FTSE Russell’s price requirements. This exclusion from the index may result in selling pressure on MULN shares, despite the company having a substantial cash reserve of over $235 million. Mullen’s market capitalization remains low at around $30 million, leading to concerns about dilution as the company recently announced a potential resale of up to 2.33 billion shares, further increasing the number of outstanding shares. The company implemented a reverse stock split to meet Nasdaq’s listing requirements, but its stock price has continued to fall, putting it at risk of delisting from the exchange and will likely have to do another reverse stock split in the near future. Mullen’s attempts to integrate artificial intelligence technology into its vehicles have not generated substantial market enthusiasm, and its optimistic outlook amid challenging financial circumstances remains unconvincing. As a result, it is advised against holding MULN stock in 2023.

Conclusion:

Extensive research across multiple sources has unveiled a wide array of opinions regarding $MULN’s trajectory in the upcoming years. While the company’s management team perceives it as severely undervalued, a critical examination of their financial standing reveals a lack of profitability and no recorded revenue to date. Nevertheless, $MULN may stand at a crucial turning point, as they embark on commercializing several products, potentially leading to revenue generation. Yet, YahooFinance’s data highlights a staggering net income loss of approximately $739 million from operating activities, indicating that positive fundamentals may remain distant in the foreseeable future.

We will update you on MULN when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by paulbr75 from Pixabay

 

Continue Reading

Featured

Unlocking Potential: Biodexa Pharmaceutical’s (NASDAQ: BDRX) MTX110 Study Progress Triggers Trading Frenzy

Published

on

 

Biodexa Pharmaceutical’s (NASDAQ: BDRX) shares have shown substantial volatility during today’s trading session, experiencing gains of nearly 150% at various points. Biodexa specializes in the development of treatments for brain cancer. More importantly, the company recently completed the enrollment and treatment phase for nine children participating in a study involving their lead asset, MTX110.

 

Allow us to provide a simplified explanation of the announcement, to enhance your understanding of the company’s efforts to improve clinical outcomes for primary and metastatic brain cancers.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

 

About MTX110 Clinical Trial:

In this particular study, the enrolled children, aged between 4 and 17 years, underwent radiation therapy as per standard medical practice. After that, they had surgery to implant a special catheter and a programmable pump directly into their tumors. The purpose of this implant is to deliver a drug called MTX110 into the tumor site. Out of the nine patients, eight have received two infusions of MTX110 via a technique called convection-enhanced delivery (CED), with different concentrations of the drug being tested.

The important update is that there have been no reports of serious side effects or toxicities related to the use of MTX110 in this study. The drug has been well-tolerated by the patients.

The study aims to evaluate the safety and effectiveness of MTX110 in treating children with DMGs, which is a highly challenging and life-threatening disease. The survival rate for patients with DMGs is very low, and current treatment options are limited. The results of this study are expected to be made public in early 2024, providing valuable information about the drug’s impact on the disease.

Insights from Retail Investors:

As previously mentioned, Microcap stocks often have a limited number of available shares, commonly referred to as a “tight” or “low” float. In the case of $BDRX, they recently underwent a reverse stock split because their stock price fell below the minimum bid compliance standard on NASDAQ. This reverse split was significant, with a ratio of one-for-eighty (1-80), and was effective on July 5th, 2023. Consequently, the number of shares available for trading decreased substantially, leading to a significant increase in trading volatility. It’s worth noting that $BDRX has one of the lowest floats we’ve observed on NASDAQ, with only 220.22k shares available for trading. Many Retail investors would consider this a “Nano-float”. Given the circumstances, it’s understandable that stocks like this can experience highly significant price fluctuations, attracting a large number of investors seeking quick gains through short-term trading strategies.

 

 

 

About Diffuse Midline Gliomas (DMGs):

DMGs is a type of brain tumor that occurs in the middle part of the brain. It cannot be surgically removed and mostly affects children. The average survival rate is around 9 to 11 months, and most patients die within a year of diagnosis. The current treatments, such as chemotherapy, are not very effective because the drugs have difficulty reaching the brain. About 1,100 people worldwide are diagnosed with DMG each year.

About MTX110:

MTX110 is a modified form of a drug called panobinostat. It is designed to be delivered directly to the tumor site through a catheter system, bypassing the blood-brain barrier. This allows for high concentrations of the drug to be delivered to the tumor while minimizing side effects. MTX110 is being studied for its effectiveness in treating recurrent glioblastoma, pediatric DMG, and recurrent medulloblastoma. Previous studies have shown promising results in laboratory tests using DMG and glioblastoma cells.

About Phase 1 Clinical Trials: 

The primary goal of a Phase 1 clinical trial is to assess the safety and tolerability of a new drug or treatment in a small group of participants. Phase 1 trials are the earliest stage of human testing and usually involve a relatively small number of healthy volunteers or patients. The main objectives of Phase 1 trials are:

Safety: Phase 1 trials aim to identify any potential side effects or adverse reactions associated with the treatment. Researchers closely monitor participants for any negative effects and determine the dose levels that can be tolerated.

Dosage determination: These trials help determine the appropriate dosage range for further studies. Researchers may administer different doses to participants to evaluate the drug’s pharmacokinetics (how the drug is absorbed, distributed, metabolized, and eliminated by the body) and determine the optimal dose for further investigation.

Pharmacokinetics and pharmacodynamics: Phase 1 trials assess how the drug is processed in the body, including its absorption, distribution, metabolism, and elimination. They also evaluate how the drug interacts with the body’s cells and affects the targeted disease or condition.

Preliminary efficacy: Although Phase 1 trials primarily focus on safety, they may also provide initial data on the treatment’s effectiveness. Researchers may evaluate early signs of efficacy or measure biomarkers to determine if the drug is having the desired effects.

Overall, the main goal of a Phase 1 clinical trial is to gather essential information about the drug’s safety profile, establish an appropriate dosage range, and lay the groundwork for further studies in subsequent phases (Phase 2 and Phase 3) to evaluate the treatment’s efficacy and potential benefits.

Conclusion:

Biodexa Ltd (NASDAQ: BDRX) has achieved another significant milestone with its lead asset, MTX110. The limited number of available shares following their stock split has resulted in rapid stock movement, attracting investors seeking quick profits from potential substantial gains. According to their presentation deck, there are several important upcoming milestones and catalysts to monitor in the coming months. These include the release of Phase 1 ‘203 study data in DMG, submission of Phase 2 IND in DMG, the publication of MAGIC-G1 study cohort A PFS data, and the initiation of the Phase 2 study in DMG.

We will update you on BDRX when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by Jarmoluk from Pixabay

 

Continue Reading

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.